Investigational drug · Phase 2
MK-3120
Also called: SKB410
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Bladder Cancer, Advanced Solid Tumors, Malignant Neoplasm.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "MK-3120"
First trial start
2022
Nov 16, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MK-3120", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bladder Cancer
- Advanced Solid Tumors
- Malignant Neoplasm
- Urinary Bladder Neoplasms
- Urothelial Carcinoma
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "MK-3120" as an intervention, largest first.
- A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06818643 · 270 participants (planned) · Start Mar 25, 2025 · Primary completion Feb 8, 2028
Drug: MK-3120 · For: Advanced Solid Tumors; Malignant Neoplasm
Sites: Birmingham, Alabama; Miami, Florida; Hackensack, New Jersey · 49 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07232602 · 55 participants (planned) · Start Feb 9, 2026 · Primary completion Jul 8, 2031
Drug: MK-3120; EV and 2 more · For: Bladder Cancer
Sites: San Francisco, California; Chicago, Illinois; New York, New York · 17 sites in all
- A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)Active, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05562830 · 48 participants (planned) · Start Nov 16, 2022 · Primary completion Feb 26, 2029
Drug: Zilovertamab vedotin; Pembrolizumab and 1 more · For: Urothelial Carcinoma
Sites: Orange, California; San Francisco, California; Aurora, Colorado · 28 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07222488 · 45 participants (planned) · Start Dec 9, 2025 · Primary completion Jul 30, 2027
Drug: MK-3120 · For: Bladder Cancer; Urinary Bladder Neoplasms
Sites: Bakersfield, California; New Brunswick, New Jersey; Myrtle Beach, South Carolina · 17 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Bladder Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- BCGPhase 38 trials
ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- VisugromabCTL-002, Visugromab RDEPhase 36 trials
CatalYm GmbH · Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma
- TAR-200JNJ-17000139, Gemcitabine-Releasing Intravesical SystemPhase 35 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Bladder Cancer
- Cretostimogene GrenadenorepvecCG0070Phase 34 trials
CG Oncology, Inc. · Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer, Urologic Cancer
- BrigimadlinBI 907828Phase 33 trials
Boehringer Ingelheim · Solid Tumours, Pancreatic Neoplasms, Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.